Ksilink builds on a synergistic network of excellence consisting of 12 members from academia, hospitals, biotech and pharma with the ambition to increase the efficiency of drug discovery and preclinical development by putting the patient at the center. For this purpose, the association conducts an integrated pipeline of patient-based drug discovery programs in the fields of muscular and neurologic disorders as well as oncology, where outstanding capacities for patient-based disease modelling and preclinical drug development from its members are combined with AI-boosted phenotypic profiling and high-content/high-throughput screening capacities of its subsidiary, Ksilink Services SAS.

Ksilink is looking for strategic partnerships in the development of their own pipeline assets and offers service activities for external parties and pharma companies.